alexa Clinical and Serological Response to Tocilizumab in Patients with Rheumatoid Arthritis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Clinical and Serological Response to Tocilizumab in Patients with Rheumatoid Arthritis

Objective: The role of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in the response to treatment for rheumatoid arthritis (RA) such as tocilizumab (TCZ) is still not completely understood. This study investigates the relationship between the presence and levels of RF and anti-CCP and clinical response to TCZ in patients with RA. Methods: This was an observational longitudinal study in 27 patients with active, long-standing RA despite previous treatment with >2 Disease-Modifying Anti Rheumatic Drugs (DMARDs) and/or steroids. Patients were treated with TCZ 8 mg/kg every 4 weeks.

Citation: Epis O, Alpini C, Marceglia S, Casu C, Giacomelli L, et al. (2013) Clinical and Serological Response to Tocilizumab in Patients with Rheumatoid Arthritis. J Med Diagn Meth 2:127.

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger